The development of heparan sulfate sugars as therapeutics: Versatility that couples stem cells, tissue engineering, and wound repair

Drug Development Research

Volumn 62, Issue 4, 2004, Pages 303-316

  Nurcombe, Victor ^a   Kumarasuriyar, Arjuna ^a   Cool, Simon M ^a  

^a INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

Author keywords

Bioscaffolds; Extracellular matrix; Growth factors; Heparin binding; Regeneration

Indexed keywords

CELL SURFACE PROTEIN; CHEMOKINE; COLLAGEN; ENOXAPARIN; FIBROBLAST GROWTH FACTOR; GLYCOPROTEIN; GLYPICAN; GROWTH FACTOR; HEPARAN SULFATE GLYCOSAMINOGLYCAN; HEPARIN; HEPARIN DERIVATIVE; PERLECAN; SYNDECAN; UNCLASSIFIED DRUG;

BLOOD CLOT LYSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; COMPLEX FORMATION; DRUG ACTIVITY; DRUG DESIGN; DRUG MARKETING; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; EXTRACELLULAR MATRIX; GLYCOCALYX; HUMAN; MORPHOGENESIS; NONHUMAN; OSTEOPOROSIS; PROTEIN PROTEIN INTERACTION; REVIEW; SEQUENCE ANALYSIS; SIDE EFFECT; STEM CELL; THROMBOCYTOPENIA; TISSUE ENGINEERING; WOUND HEALING;

EID: 11344254692     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10395     Document Type: Review

References (90)

1. Arikawa-Hirasawa E, Le AH, Nishino I, Nonaka I, Ho NC, Francomano CA, Govindraj P, Hassell JR, Devaney JM, Spranger J, and others. 2002. Structural and functional mutations of the perlecan gene cause Schwartz-Jampel syndrome, with myotonic myopathy and chondrodysplasia. Am J Hum Genet 70:1368-1375.
2. Badylak SF. 2002. The extracellular matrix as a scaffold for tissue reconstruction. Semin Cell Dev Biol 13:377-383.
3. Bellin R, Capila I, Lincecum J, Park PW, Reizes O, Bernfield MR. 2002. Unlocking the secrets of syndecans: transgenic organisms as a potential key. Glycoconj J 19:295-304.
4. Bernfield M, Hinkes MT, Gallo RL. 1993. Developmental expression of the syndecans: possible function and regulation. Dev Suppl:205-212.
5. Brickman YG, Ford MD, Small DH, Bartlett PF, Nurcombe V. 1995. Heparan sulfates mediate the binding of basic fibroblast growth factor to a specific receptor on neural precursor cells. J Biol Chem 270:24941-24948.
6. Brickman YG, Ford MD, Gallagher JT, Nurcombe V, Bartlett PF, Turnbull JE. 1998a. Structural modification of fibroblast growth factor-binding heparan sulfate at a determinative stage of neural development. J Biol Chem 273:4350-4359.
7. Brickman YG, Nurcombe V, Ford MD, Gallagher JT, Bartlett PF, Turnbull JE. 1998b. Structural comparison of fibroblast growth factor-specific heparan sulfates derived from a growing or differentiating neuroepithelial cell line. Glycobiology 8:463-471.
8. Casu B, Lindahl U. 2001. Structure and biological interactions of heparin and heparan sulfate. Adv Carbohydr Chem Biochem 57:159-206.
9. Chen RL, Lander AD. 2001. Mechanisms underlying preferential assembly of heparan sulfate on glypican-1. J Biol Chem 276:7507-7517.
10. Chipperfield H, Bedi KS, Cool SM, Nurcombe V. 2002. Heparan sulfates isolated from adult neural progenitor cells can direct phenotypic maturation. Int J Dev Biol 46:661-670.
11. Cool SM, Sayer RE, van Heumen WR, Pickles JO, Nurcombe V. 2002. Temporal and spatial expression of fibroblast growth factor receptor 4 isoforms in murine tissues. Histochem J 34:291-297.
12. Costell M, Gustafsson E, Aszodi A, Morgelin M, Bloch W, Hunziker E, Addicks K, Timpl R, Fassler R. 1999. Perlecan maintains the integrity of cartilage and some basement membranes. J Cell Biol 147:1109-1122.
13. Czyz J, Wobus A. 2001. Embryonic stem cell differentiation: the role of extracellular factors. Differentiation 68:167-174.
14. Daniel TO, Abrahamson D. 2000. Endothelial signal integration in vascular assembly. Annu Rev Physiol 62:649-671.
15. Delehedde M, Lyon M, Sergeant N, Rahmoune H, Fernig DG. 2001. Proteoglycans: pericellular and cell surface multireceptors that integrate external stimuli in the mammary gland. J Mammary Gland Biol Neoplasia 6:253-273.
16. Esko JD, Lindahl U. 2001. Molecular diversity of heparan sulfate. J Clin Invest 108:169-173.
17. Fagan AM, Suhr ST, Lucidi-Phillipi CA, Peterson DA, Holtzman DM, Gage FH. 1997. Endogenous FGF-2 is important for cholinergic sprouting in the denervated hippocampus. J Neurosci 17:2499-2511.
18. Fernig DG, Chen HL, Rahmoune H, Descamps S, Boilly B, Hondermarck H. 2000. Differential regulation of FGF-1 and -2 mitogenic activity is related to their kinetics of binding to heparan sulfate in MDA-MB-231 human breast cancer cells. Biochem Biophys Res Commun 267:770-776.
19. Gage FH. 2000. Mammalian neural stem cells. Science 287:1433-1438.
20. Gallagher JT 2001. Heparan sulfate: growth control with a restricted sequence menu. J Clin Invest 108:357-361.
21. Guimond S, Turner K, Kita M, Ford-Perriss M, Turnbull J. 2001. Dynamic biosynthesis of heparan sulphate sequences in developing mouse brain: a potential regulatory mechanism during development. Biochem Soc Trans 29(Pt 2):177-181.
22. Guimond SE, Turnbull JE. 1999. Fibroblast growth factor receptor signalling is dictated by specific heparan sulphate saccharides. Curr Biol 9:1343-1346.
23. Hassell J, Yamada Y, Arikawa-Hirasawa E. 2002. Role of perlecan in skeletal development and diseases. Glycoconj J 19:263-267.
24. Hogan BL, Kolodziej PA. 2002. Organogenesis: molecular mechanisms of tubulogenesis. Nat Rev Genet 3:513-523.
25. Iozzo RV 1998. Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem 67:609-652.
26. Jemth P, Kreuger J, Kusche-Gullberg M, Sturiale L, Gimenez-Gallego G, Lindahl U. 2002. Biosynthetic oligosaccharide libraries for identification of protein-binding heparan sulfate motifs. Exploring the structural diversity by screening for fibroblast growth factor (FGF)1 and FGF2 binding. J Biol Chem 277:30567-30573.
27. Kato M, Wang H, Bernfield M, Gallagher JT, Turnbull JE. 1994. Cell surface syndecan-1 on distinct cell types differs in fine structure and ligand binding of its heparan sulfate chains. J Biol Chem 269:18881-18890.
28. Kleinman HK, Philp D, Hoffman MP. 2003. Role of the extracellular matrix in morphogenesis. Curr Opin Biotechnol 14:526-532.
29. Kuberan B, Lech M, Zhang L, Wu ZL, Beeler DL, Rosenberg RD. 2002. Analysis of heparan sulfate oligosaccharides with ion pair-reverse phase capillary high performance liquid chromatography-microelectrospray ionization time-of-flight mass spectrometry. J Am Chem Soc 124:8707-8718.
30. Kuberan B, Lech MZ, Beeler DL, Wu ZL, Rosenberg RD. 2003. Enzymatic synthesis of antithrombin III-binding heparan sulfate pentasaccharide. Nat Biotechnol 21:1343-1346.
31. Lander AD. 1998. Proteoglycans: master regulators of molecular encounter? Matrix Biol 17:465-472.
32. Lander AD, Selleck SB. 2000. The elusive functions of proteoglycans: in vivo veritas. J Cell Biol 148:227-232.
33. Lander AD, Stipp CS, Ivins JK. 1996. The glypican family of heparan sulfate proteoglycans: major cell-surface proteoglycans of the developing nervous system. Perspect Dev Neurobiol 3:347-358.
34. Lawrence R, Kuberan B, Lech M, Beeler DL, Rosenberg RD. 2004. Mapping critical biological motifs and biosynthetic pathways of heparan sulfate. Glycobiology 14:467-479.
35. Lin X, Buff EM, Perrimon N, Michelson AM. 1999. Heparan sulfate proteoglycans are essential for FGF receptor signaling during Drosophila embryonic development. Development 126:3715-3723.
36. Lindahl U. 1999. What else can 'Heparin' do? Haemostasia 29(suppl S1):38-47.
37. Lindahl U. 2000. 'Heparin' - from anticoagulant drug into the new biology. Glycoconj J 17:597-605.
38. Linhardt RJ, Wang HM, Ampofo SA. 1992a. New methodologies in heparin structure analysis and the generation of LMW heparins. Adv Exp Med Biol 313:37-47.
39. Linhardt RJ, Wang HM, Loganathan D, Bae JH. 1992b. Search for the heparin antithrombin III-binding site precursor. J Biol Chem 267:2380-2387.
40. Lortat-Jacob H, Turnbull JE, Grimaud JA. 1995. Molecular organization of the interferon gamma-binding domain in heparan sulphate. Biochem J 310(pt 2):497-505.
41. Lyon M, Gallagher JT. 1998. Bio-specific sequences and domains in heparan sulphate and the regulation of cell growth and adhesion. Matrix Biol 17:485-493.
42. Maccarana M, Sakura Y, Tawada A, Yoshida K, Lindahl U. 1996. Domain structure of heparan sulfates from bovine organs. J Biol Chem 271:17804-17810.
43. Mann BK, West JL. 2002. Cell adhesion peptides alter smooth muscle cell adhesion, proliferation, migration, and matrix protein synthesis on modified surfaces and in polymer scaffolds. J Biomed Mater Res 60:86-93.
44. Martin GR. 1998. The roles of FGFs in the early development of vertebrate limbs. Genes Dev 12:1571-1586.
45. Merry CL, Lyon M, Deakin JA, Hopwood JJ, Gallagher JT. 1999. Highly sensitive sequencing of the sulfated domains of heparan sulfate. J Biol Chem 274:18455-18462.
46. Naggi A, Torri G, Casu B, Oreste P, Zoppetti G, Li JP, Lindahl U. 2001. Toward a biotechnological heparin through combined chemical and enzymatic modification of the Escherichia coli K5 polysaccharide. Semin Thromb Hemost 27:437-443.
47. Noonan DM, Fulle A, Valente P, Gai S, Horigan E, Sasaki M, Yamada Y, Hassell JR. 1991. The complete sequence of perlecan, a basement membrane heparan sulfate proteoglycan, reveals extensive similarity with laminin A chain, low density lipoprotein-receptor, and the neural cell adhesion molecule. J Biol Chem 266:22939-22947.
48. Noonan DM, Hassell JR. 1993. Perlecan, the large low-density proteoglycan of basement membranes: structure and variant forms. Kidney Int 43:53-60.
49. Nurcombe V, Ford MD, Wildschut JA, Bartlett PF. 1993. Developmental regulation of neural response to FGF-1 and FGF-2 by heparan sulfate proteoglycan. Science 260:103-106.
50. Nurcombe V, Smart CE, Chipperfield H, Cool SM, Boilly B, Hondermarck H. 2000. The proliferative and migratory activities of breast cancer cells can be differentially regulated by heparan sulfates. J Biol Chem 275:30009-30018.
51. Nurcombe V, Wreford NG, Bertram JF. 2001. Stereological estimation of neuronal number. The optical disector/cavalieri combination. Methods Mol Biol 169:251-268.
52. Ornitz DM. 2000. FGFs, heparan sulfate and FGFRs: complex interactions essential for development. Bioessays 22:108-112.
53. Ornitz DM, Itoh N. 2001. Fibroblast growth factors. Genome Biol 2:REVIEWS3005.
54. Patel N, Padera R, Sanders GH, Cannizzaro SM, Davies MC, Langer R, Roberts CJ, Tendler SJ, Williams PM, Shakesheff KM. 1998. Spatially controlled cell engineering on biodegradable polymer surfaces. FASEB J 12:1447-1454.
55. Pellegrini L, Burke DF, von Delft F, Mulloy B, Blundell TL. 2000. Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin. Nature 407:1029-1034.
56. Perrimon N, Bernfield M. 2000. Specificities of heparan sulphate proteoglycans in developmental processes. Nature 404:725-728.
57. Perrimon N, Bernfield M. 2001. Cellular functions of proteoglycans - an overview. Semin Cell Dev Biol 12:65-67.
58. Pilia G, Hughes-Benzie RM, MacKenzie A, Baybayan P, Chen EY, Huber R, Neri G, Cao A, Forabosco A, Schlessinger D. 1996. Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nat Genet 12:241-247.
59. Powell AK, Fernig DG, Turnbull JE. 2002. Fibroblast growth factor receptors 1 and 2 interact differently with heparin/heparan sulfate. Implications for dynamic assembly of a ternary signaling complex. J Biol Chem 277:28554-28563.
60. Powell AK, Yates EA, Fernig DG, Turnbull JE. 2004. Interactions of heparin/heparan sulfate with proteins: appraisal of structural factors and experimental approaches. Glycobiology 14:17R-30R.
61. Pye DA, Gallagher JT 1999. Monomer complexes of basic fibroblast growth factor and heparan sulfate oligosaccharides are the minimal functional unit for cell activation. J Biol Chem 274:13456-13461.
62. Pye DA, Vives RR, Turnbull JE, Hyde P, Gallagher JT. 1998. Heparan sulfate oligosaccharides require 6-O-sulfation for promotion of basic fibroblast growth factor mitogenic activity. J Biol Chem 273:22936-22942.
63. Pye DA, Vives RR, Hyde P, Gallagher JT 2000. Regulation of FGF-1 mitogenic activity by heparan sulfate oligosaccharides is dependent on specific structural features: differential requirements for the modulation of FGF-1 and FGF-2. Glycobiology 10:1183-1192.
64. Rahmoune H, Chen HL, Gallagher JT, Rudland PS, Fernig DG. 1998. Interaction of heparan sulfate from mammary cells with acidic fibroblast growth factor (FGF) and basic FGF. Regulation of the activity of basic FGF by high and low affinity binding sites in heparan sulfate. J Biol Chem 273:7303-7310.
65. Rapraeger AC, Krufka A, Olwin BB. 1991. Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science 252:1705-178.
66. Ray J, Hogg J, Beutler AS, Takayama H, Baird A, Gage FH. 1995. Expression of biologically active basic fibroblast growth factor by genetically modified rat primary skin fibroblasts. J Neurochem 64:503-513.
67. Rhomberg AJ, Shriver Z, Biemann K, Sasisekharan R. 1998. Mass spectrometric evidence for the enzymatic mechanism of the depolymerization of heparin-like glycosaminoglycans by heparinase II. Proc Natl Acad Sci USA 95:12232-12237.
68. Ruhrberg C, Gerhardt H, Golding M, Watson R, Ioannidou S, Fujisawa H, Betsholtz C, Shima DT. 2002. Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev 16:2684-2698.
69. Sanderson RD, Turnbull JE, Gallagher JT, Lander AD. 1994. Fine structure of heparan sulfate regulates syndecan-1 function and cell behavior. J Biol Chem 269:13100-13106.
70. Sasisekharan R, Venkataraman G. 2000. Heparin and heparan sulfate: biosynthesis, structure and function. Curr Opin Chem Biol 4:626-631.
71. Saunders S, Jalkanen M, O'Farrell S, Bernfield M. 1989. Molecular cloning of syndecan, an integral membrane proteoglycan. J Cell Biol 108:1547-1556.
72. Schlessinger J, Plotnikov AN, Ibrahimi OA, Eliseenkova AV, Yeh BK, Yayon A, Linhardt RJ, Mohammadi M. 2000. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol Cell 6:743-750.
73. Schwartz RE, Reyes M, Koodie L, Jiang Y, Blackstad M, Lund T, Lenvik T, Johnson S, Hu WS, Verfaillie CM. 2002. Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells. J Clin Invest 109:1291-1302.
74. Shen T, Sonoda G, Hamid J, Li M, Filmus J, Buick RN, Testa JR. 1997. Mapping of the Simpson-Golabi-Behmel overgrowth syndrome gene (GPC3) to chromosome X in human and rat by fluorescence in situ hybridization. Mamm Genome 8:72.
75. Shriver Z, Sundaram M, Venkataraman G, Fareed J, Linhardt R, Biemann K, Sasisekharan R. 2000. Cleavage of the antithrombin III binding site in heparin by heparinases and its implication in the generation of low molecular weight heparin. Proc Natl Acad Sci USA 97:10365-10370.
76. Sieg DJ, Hauck CR, Schlaepfer DD. 1999. Required role of focal adhesion kinase (FAK) for integrin-stimulated cell migration. J Cell Sci 112(pt 16):2677-2691.
77. Song HH, Filmus J. 2002. The role of glypicans in mammalian development. Biochim Biophys Acta 1573:241-246.
78. Turnbull J, Powell A, Guimond S. 2001. Heparan sulfate: decoding a dynamic multifunctional cell regulator. Trends Cell Biol 11:75-82.
79. Turnbull JE. 2001a. Analytical and preparative strong anion-exchange HPLC of heparan sulfate and heparin saccharides. Methods Mol Biol 171:141-147.
80. Turnbull JE. 2001b. Integral glycan sequencing of heparan sulfate and heparin saccharides. Methods Mol Biol 171:129-139.
81. Turnbull JE, Gallagher JT. 1991. Distribution of iduronate 2-sulphate residues in heparan sulphate. Evidence for an ordered polymeric structure. Biochem J 273 (pt 3): 553-559.
82. Turnbull JE, Hopwood JJ, Gallagher JT. 1999. A strategy for rapid sequencing of heparan sulfate and heparin saccharides. Proc Natl Acad Sci USA 96:2698-2703.
83. Vihinen T, Auvinen P, Alanen-Kurki L, Jalkanen M. 1993. Structural organization and genomic sequence of mouse syndecan-1 gene. J Biol. Chem 268:17261-17269.
84. Vives RR, Pye DA, Salmivirta M, Hopwood JJ, Lindahl U, Gallagher JT. 1999. Sequence analysis of heparan sulphate and heparin oligosaccharides. Biochem J 339 (pt 3):767-773.
85. Witt DP, Lander AD. 1994. Differential binding of chemokines to glycosaminoglycan subpopulations. Curr Biol 4:394-400.
86. Wu ZL, Zhang L, Beeler DL, Kuberan B, Rosenberg RD. 2002. A new strategy for defining critical functional groups on heparan sulfate. FASEB J 16:539-545.
87. Wu ZL, Zhang L, Yabe T, Kuberan B, Beeler DL, Love A, Rosenberg RD. 2003. The involvement of heparan sulfate (HS) in FGF1/HS/FGFR1 signaling complex. J Biol Chem 278:17121-17129.
88. Xu C, Inokuma MS, Denham J, Golds K, Kundu P, Gold JD, Carpenter MK. 2001. Feeder-free growth of undifferentiated human embryonic stem cells. Nat Biotechnol 19:971-974.
89. Yates EA, Guimond SE, Turnbull JE. 2004. Highly diverse heparan sulfate analogue libraries: providing access to expanded areas of sequence space for bioactivity screening. J Med Chem 47:277-280.
90. Yayon A, Klagsbrun M, Esko JD, Leder P, Ornitz DM. 1991. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 64:841-848.